Study Investigating Safety, Tolerability and Effectiveness of Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction of New Onset Non-M3 Acute Myelid Leukemia
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2018
Price : $35 *
At a glance
- Drugs Venetoclax (Primary) ; Cytarabine; Fludarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms V-FIRST
- 12 Oct 2018 Planned End Date changed from 1 Jun 2020 to 1 Sep 2020.
- 12 Oct 2018 Planned primary completion date changed from 1 Jun 2020 to 1 Aug 2020.
- 12 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Dec 2018.